At their June 2000 meeting, members of NIDA's Community Epidemiology Work Group (CEWG)* shared the following information.
Because stimulant medicines such as methylphenidate do have potential for abuse, the U.S. Drug Enforcement Administration (DEA) has placed stringent, Schedule II controls on their manufacture, distribution, and prescription. For example, DEA requires special licenses for these activities, and prescription refills are not allowed. States may impose further regulations, such as limiting the number of dosage units per prescription.
Related Resources
• Ritalin Health Effects
Source: The National Institute on Drug Abuse (NIDA).

